3 Aug, 2010 in
News & Articles by
admin
|
Oxford BioMedica Plc, a team of cancer immunologists at Cardiff University as well as Jason Lester, an oncologist at Velindre Cancer Centre in Cardiff, possess entered a collaborative joint venture to evaluate the effect of TroVax on mesothelioma when administered with chemotherapy. The study will begin later this year with funding by the June Hancock Mesothelioma Research Fund. For the filled story, go to RTT News. |